Skip to content

Qingre Huashi Formula Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Controlled Trial

Qingre Huashi Formula Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019416
Enrollment
Unknown
Registered
2018-11-10
Start date
2018-11-12
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive diseases linked to HP infection

Interventions

Group 1:14 days' regimen of the combined treatment of bismuth
Group 2:14 days' regimen of the combined treatment of bismuth + Qin-Re-Hua-Shi method

Sponsors

Peking Univeisity First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Chronic gastritis or inactive ulcer were diagnosed by endoscopy and pathological examination. 2. HP infection was diagnosed by urea 13C breath test, endoscopic rapid urease test or stool antigen test. 3. Uneradicated treatment, no antibiotics within one month, no acid suppressant and gastric mucosal protectant within 2 weeks; 4. The syndrome differentiation of TCM is spleen and stomach dampness heat syndrome, and the diagnostic criteria of spleen and stomach dampness heat syndrome refer to the consensus opinion of TCM diagnosis and treatment of chronic gastritis (2017); 5. Aged 18-70 years male and female; 6. The subjects (or legal representatives) voluntarily consented and signed informed consent and were able to follow the research program during the study.

Exclusion criteria

Exclusion criteria: 1. Endoscopic examination showed active ulcer; 2. Having a history of gastric surgery; 3. Long-term administration of non-steroidal anti-inflammatory drugs and PPI,H2RA, mucosal protectants; 4. Severe diseases, such as severe liver disease, heart disease, kidney disease, nausea, tumor and alcoholism, which were evaluated by the impact study; 5. Allergy to the drugs used in this study; 6. Having participated in other drug clinical studies within 3 months before participating in this project; 7. Patients could not express their subjective feelings correctly and could not cooperate with each other; 8. Pregnant women.

Design outcomes

Primary

MeasureTime frame
The eradication rate of H.pylori;

Secondary

MeasureTime frame
Score of symptoms;

Countries

China

Contacts

Public ContactHUI YE

Peking Univeisity First Hospital

brightleaf723@163.com+86 010-83572351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026